Status of drug development for the prevention and treatment of osteoporosis

Peter Schwarz*, Niklas Rye Jorgensen, Bo Abrahamsen

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftReviewForskningpeer review


    Introduction: The metabolic bone disease osteoporosis is a growing health and health-economic problem worldwide. Bisphosphonates are the most widely used antiresorptive medication and the de facto gold standard in fracture prophylaxis all over the world, in conjunction with calcium and vitamin D supplementation. Several new medications for the treatment of postmenopausal osteoporosis are in the pipeline. Areas covered: The authors present the most recent studies on new and current antiresorptive as well as anabolic drugs. Specifically, the authors present the current knowledge on drugs directed against cathepsin K and sclerostin as well as the new pathways of interest from preclinical studies. Expert opinion: New scientific results have identified novel signaling pathways as potential targets for future development of anti-osteoporotic drugs. The treatments close to marketing at the moment are odanacatib and romosozumab and these are both promising new medications based on bone mineral density results, safety profile and administration. Theoretically, romosozumab may hold the potential to be a drug to 'cure' even advanced stages of osteoporosis with short-term treatment. However, safety, fracture data and cost are key elements that will determine the extent of use.

    Sider (fra-til)245-253
    Antal sider9
    TidsskriftExpert Opinion on Drug Discovery
    Udgave nummer3
    StatusUdgivet - 1 mar. 2014


    Udforsk hvilke forskningsemner 'Status of drug development for the prevention and treatment of osteoporosis' indeholder.